

Cristina Mussini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5561527/publications.pdf>

Version: 2024-02-01

410
papers

17,187
citations

20817

60
h-index

21540

114
g-index

417
all docs

417
docs citations

417
times ranked

21546
citing authors

#	ARTICLE	IF	CITATIONS
1	Combination Antiretroviral Therapy and the Risk of Myocardial Infarction. <i>New England Journal of Medicine</i> , 2003, 349, 1993-2003.	27.0	1,560
2	Tocilizumab in patients with severe COVID-19: a retrospective cohort study. <i>Lancet Rheumatology</i> , The, 2020, 2, e474-e484.	3.9	772
3	Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. <i>Nature Communications</i> , 2020, 11, 3434.	12.8	636
4	Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. <i>Lancet</i> , The, 2019, 393, 2428-2438.	13.7	627
5	Use in routine clinical practice of two commercial blood tests for diagnosis of infection with <i>Mycobacterium tuberculosis</i> : a prospective study. <i>Lancet</i> , The, 2006, 367, 1328-1334.	13.7	468
6	Common Genetic Variation and the Control of HIV-1 in Humans. <i>PLoS Genetics</i> , 2009, 5, e1000791.	3.5	377
7	Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. <i>Lancet</i> , The, 2004, 364, 51-62.	13.7	303
8	Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by <i>Klebsiella pneumoniae</i> Carbapenemase-producing <i>K. pneumoniae</i> . <i>Clinical Infectious Diseases</i> , 2019, 68, 355-364.	5.8	265
9	Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. <i>Lancet</i> , The, 2019, 393, 143-155.	13.7	265
10	Seven Versus 14 Days of Antibiotic Therapy for Uncomplicated Gram-negative Bacteremia: A Noninferiority Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2019, 69, 1091-1098.	5.8	256
11	CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. <i>Lancet HIV</i> , the, 2015, 2, e98-e106.	4.7	249
12	Long-term consequences of COVID-19: research needs. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1115-1117.	9.1	241
13	All-cause mortality in treated HIV-infected adults with CD4 \geq 500/mm ³ compared with the general population: evidence from a large European observational cohort collaboration. <i>International Journal of Epidemiology</i> , 2012, 41, 433-445.	1.9	217
14	Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 565-575.	9.1	217
15	Ageing and inflammation in patients with HIV infection. <i>Clinical and Experimental Immunology</i> , 2016, 187, 44-52.	2.6	214
16	Incidence of Tuberculosis among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy in Europe and North America. <i>Clinical Infectious Diseases</i> , 2005, 41, 1772-1782.	5.8	197
17	Combination therapy for carbapenem-resistant Gram-negative bacteria. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2305-2309.	3.0	179
18	Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. <i>Annals of Neurology</i> , 2008, 63, 213-221.	5.3	167

#	ARTICLE	IF	CITATIONS
19	Cytomegalovirus Coinfection Is Associated With an Increased Risk of Severe Non-AIDS-Defining Events in a Large Cohort of HIV-Infected Patients. <i>Journal of Infectious Diseases</i> , 2015, 211, 178-186.	4.0	146
20	CD4 Cell Count and the Risk of AIDS or Death in HIV-Infected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load: A Longitudinal Cohort Study from COHERE. <i>PLoS Medicine</i> , 2012, 9, e1001194.	8.4	145
21	Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. <i>Clinical Infectious Diseases</i> , 2014, 58, 1312-1321.	5.8	140
22	Performance of Tests for Latent Tuberculosis in Different Groups of Immunocompromised Patients. <i>Chest</i> , 2009, 136, 198-204.	0.8	137
23	Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1899-1913.	2.6	137
24	A frailty index predicts survival and incident multimorbidity independent of markers of HIV disease severity. <i>Aids</i> , 2015, 29, 1633-1641.	2.2	136
25	Altered bioenergetics and mitochondrial dysfunction of monocytes in patients with COVID-19 pneumonia. <i>EMBO Molecular Medicine</i> , 2020, 12, e13001.	6.9	133
26	Prevalence, Associated Factors, and Prognostic Determinants of AIDS-Related Toxoplasmic Encephalitis in the Era of Advanced Highly Active Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2004, 39, 1681-1691.	5.8	131
27	One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. <i>Patient Preference and Adherence</i> , 2010, 4, 115.	1.8	130
28	Ceftazidime-Avibactam Use for <i>Klebsiella pneumoniae</i> Carbapenemase-Producing <i>K. pneumoniae</i> Infections: A Retrospective Observational Multicenter Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 1664-1676.	5.8	130
29	Brief Report. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, 58-64.	2.1	128
30	Ceftolozane/tazobactam for the treatment of serious <i>Pseudomonas aeruginosa</i> infections: a multicentre nationwide clinical experience. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 408-415.	2.5	120
31	Mitochondria alterations and dramatic tendency to undergo apoptosis in peripheral blood lymphocytes during acute HIV syndrome. <i>Aids</i> , 1997, 11, 19-26.	2.2	118
32	Discontinuation of Maintenance Therapy for Cryptococcal Meningitis in Patients with AIDS Treated with Highly Active Antiretroviral Therapy: An International Observational Study. <i>Clinical Infectious Diseases</i> , 2004, 38, 565-571.	5.8	118
33	Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. <i>Clinical Infectious Diseases</i> , 2018, 66, 893-903.	5.8	105
34	Discontinuation of Primary Prophylaxis for <i>Pneumocystis carinii</i> Pneumonia and Toxoplasmic Encephalitis in Human Immunodeficiency Virus Type 1-Infected Patients: The Changes in Opportunistic Prophylaxis Study. <i>Journal of Infectious Diseases</i> , 2000, 181, 1635-1642.	4.0	103
35	Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. <i>Journal of Translational Medicine</i> , 2020, 18, 405.	4.4	98
36	Is It Safe to Discontinue Primary <i>Pneumocystis jirovecii</i> Pneumonia Prophylaxis in Patients with Virologically Suppressed HIV Infection and a CD4 Cell Count ≥ 200 Cells/ $\mu</math>L?. Clinical Infectious Diseases, 2010, 51, 611-619.$	5.8	96

#	ARTICLE	IF	CITATIONS
37	Expansion of plasmablasts and loss of memory B cells in peripheral blood from COVID-19 patients with pneumonia. <i>European Journal of Immunology</i> , 2020, 50, 1283-1294.	2.9	95
38	Therapeutic Immunization with HIV-1 Tat Reduces Immune Activation and Loss of Regulatory T-Cells and Improves Immune Function in Subjects on HAART. <i>PLoS ONE</i> , 2010, 5, e13540.	2.5	94
39	Identification and characterization of a SARS-CoV-2 specific CD8+ T cell response with immunodominant features. <i>Nature Communications</i> , 2021, 12, 2593.	12.8	94
40	The Incidence of AIDS-Defining Illnesses at a Current CD4 Count ≥ 200 Cells/ μ L in the Post-Combination Antiretroviral Therapy Era. <i>Clinical Infectious Diseases</i> , 2013, 57, 1038-1047.	5.8	92
41	SARS-CoV-2, the Virus that Causes COVID-19: Cytometry and the New Challenge for Global Health. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2020, 97, 340-343.	1.5	91
42	Mitochondrial Functionality and Mitochondrial DNA Content in Lymphocytes of Vertically Infected Human Immunodeficiency Virus-Positive Children with Highly Active Antiretroviral Therapy-Related Lipodystrophy. <i>Journal of Infectious Diseases</i> , 2002, 185, 299-305.	4.0	90
43	Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study. <i>European Journal of Internal Medicine</i> , 2020, 82, 38-47.	2.2	88
44	Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: The Multicenter Italian CORIST Study. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1054-1065.	3.4	87
45	Increased plasma levels of extracellular mitochondrial DNA during HIV infection: A new role for mitochondrial damage-associated molecular patterns during inflammation. <i>Mitochondrion</i> , 2011, 11, 750-755.	3.4	84
46	Stable changes in CD4+ T lymphocyte miRNA expression after exposure to HIV-1. <i>Blood</i> , 2012, 119, 6259-6267.	1.4	83
47	Death rates in HIV-positive antiretroviral-naïve patients with CD4 count greater than 350 cells per μ L in Europe and North America: a pooled cohort observational study. <i>Lancet, The</i> , 2010, 376, 340-345.	13.7	82
48	Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital. <i>Clinical Microbiology and Infection</i> , 2006, 12, 75-80.	6.0	81
49	Aging with HIV vs. HIV Seroconversion at Older Age: A Diverse Population with Distinct Comorbidity Profiles. <i>PLoS ONE</i> , 2015, 10, e0118531.	2.5	81
50	Low Frequency of Severe Hepatotoxicity and Association With HCV Coinfection in HIV-Positive Patients Treated With HAART. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001, 28, 114-123.	2.1	79
51	Hypokalemia in Patients with COVID-19. <i>Clinical and Experimental Nephrology</i> , 2021, 25, 401-409.	1.6	78
52	MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naïve HIV-positive patients. <i>Aids</i> , 2003, 17, 1696-1698.	2.2	77
53	Highlights of the 2017 European <sc>AIDS</sc> Clinical Society (EACS) Guidelines for the treatment of adult <sc>HIV</sc>-positive persons version 9.0. <i>HIV Medicine</i> , 2018, 19, 309-315.	2.2	77
54	Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients. <i>BMC Infectious Diseases</i> , 2017, 17, 215.	2.9	76

#	ARTICLE	IF	CITATIONS
55	Late Presenters in an HIV Surveillance System in Italy During the Period 1992-2006. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2008, 49, 282-286.	2.1	74
56	Massive Activation of Immune Cells with an Intact T Cell Repertoire in Acute Human Immunodeficiency Virus Syndrome. <i>Journal of Infectious Diseases</i> , 1995, 172, 105-112.	4.0	72
57	Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study). <i>Clinical Microbiology and Infection</i> , 2020, 26, 1545-1553.	6.0	71
58	Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant Enterobacterales. <i>Antibiotics</i> , 2020, 9, 71.	3.7	68
59	Bloodstream infections caused by carbapenem-resistant <i>Acinetobacter baumannii</i> : Clinical features, therapy and outcome from a multicenter study. <i>Journal of Infection</i> , 2019, 79, 130-138.	3.3	67
60	The Importance of Understanding the Stages of COVID-19 in Treatment and Trials. <i>AIDS Reviews</i> , 2021, 23, 40-47.	1.0	66
61	Access to Antiretroviral Treatment, Incidence of Sustained Therapy Interruptions, and Risk of Clinical Events According to Sex. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2003, 34, 184-190.	2.1	64
62	Increased Mitochondrial Dna Content in Peripheral Blood Lymphocytes from HIV-Infected Patients with Lipodystrophy. <i>Antiviral Therapy</i> , 2003, 8, 315-321.	1.0	64
63	Aging with HIV. <i>Current HIV/AIDS Reports</i> , 2019, 16, 475-481.	3.1	63
64	Persistent inflammation in HIV infection: Established concepts, new perspectives. <i>Immunology Letters</i> , 2014, 161, 184-188.	2.5	61
65	Aging with HIV infection: A journey to the center of inflammAIDS, immunosenescence and neuroHIV. <i>Immunology Letters</i> , 2014, 162, 329-333.	2.5	59
66	Effect of treatment interruption monitored by CD4 cell count on mitochondrial DNA content in HIV-infected patients: a prospective study. <i>Aids</i> , 2005, 19, 1627-1633.	2.2	56
67	Incidence of Malignancies in HIV-Infected Patients and Prognostic Role of Current CD4 Cell Count: Evidence from a Large Italian Cohort Study. <i>Clinical Infectious Diseases</i> , 2010, 50, 1316-1321.	5.8	56
68	Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy113.	0.9	56
69	Physician Estimates of Adherence and the Patient-Physician Relationship as a Setting to Improve Adherence to Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 31, S158-S162.	2.1	55
70	HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial. <i>Retrovirology</i> , 2015, 12, 33.	2.0	55
71	Pretreatment CD4 Cell Slope and Progression to AIDS or Death in HIV-Infected Patients Initiating Antiretroviral Therapy—The CASCADE Collaboration: A Collaboration of 23 Cohort Studies. <i>PLoS Medicine</i> , 2010, 7, e1000239.	8.4	54
72	Risk of Developing Specific AIDS-Defining Illnesses in Patients Coinfected with HIV and Hepatitis C Virus With or Without Liver Cirrhosis. <i>Clinical Infectious Diseases</i> , 2009, 49, 612-622.	5.8	53

#	ARTICLE	IF	CITATIONS
73	Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. <i>Aids</i> , 2008, 22, 2461-2469.	2.2	51
74	Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASC), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid). <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1-18.	3.3	49
75	Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacteriales Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study). <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa139.	0.9	49
76	Features of 'CD4-exploders', HIV-positive patients with an optimal immune reconstitution after potent antiretroviral therapy. <i>Aids</i> , 2002, 16, 1609-1616.	2.2	48
77	Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy. <i>Aids</i> , 2008, 22, 1769-1778.	2.2	48
78	The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study. <i>Retrovirology</i> , 2014, 11, 49.	2.0	48
79	Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium. <i>Lancet HIV</i> , 2022, 9, e474-e485.	4.7	48
80	Interruption of Highly Active Antiretroviral Therapy in HIV Clinical Practice. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2005, 38, 407-416.	2.1	46
81	The protease inhibitor atazanavir triggers autophagy and mitophagy in human preadipocytes. <i>Aids</i> , 2012, 26, 2017-2026.	2.2	46
82	Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the IcoNa cohort. <i>Journal of the International AIDS Society</i> , 2019, 22, e25227.	3.0	46
83	Cytotoxic granule release dominates gag-specific CD4+ T-cell response in different phases of HIV infection. <i>Aids</i> , 2010, 24, 947-957.	2.2	45
84	Late Presenters in New HIV Diagnoses from An Italian Cohort of HIV-Infected Patients: Prevalence and Clinical Outcome. <i>Antiviral Therapy</i> , 2011, 16, 1103-1112.	1.0	45
85	Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe. <i>HIV Medicine</i> , 2017, 18, 171-180.	2.2	45
86	Genetic polymorphisms of Fas (CD95) and Fas ligand (CD178) influence the rise in CD4+ T cell count after antiretroviral therapy in drug-naïve HIV-positive patients. <i>Immunogenetics</i> , 2005, 57, 628-635.	2.4	44
87	Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study. <i>Clinical Infectious Diseases</i> , 2017, 65, 1316-1326.	5.8	44
88	Correlates of frailty phenotype and frailty index and their associations with clinical outcomes. <i>HIV Medicine</i> , 2017, 18, 764-771.	2.2	44
89	Machine learning in predicting respiratory failure in patients with COVID-19 pneumonia—Challenges, strengths, and opportunities in a global health emergency. <i>PLoS ONE</i> , 2020, 15, e0239172.	2.5	43
90	Mitochondria in the pathogenesis of lipodystrophy induced by anti-HIV antiretroviral drugs: actors or bystanders?. <i>BioEssays</i> , 2001, 23, 1070-1080.	2.5	42

#	ARTICLE	IF	CITATIONS
91	Triple-Class Virologic Failure in HIV-Infected Patients Undergoing Antiretroviral Therapy for Up to 10 Years. <i>Archives of Internal Medicine</i> , 2010, 170, 410-419.	3.8	42
92	Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 119-127.	9.1	41
93	Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients. <i>Annals of Internal Medicine</i> , 2017, 166, 9.	3.9	41
94	Epidemiology and Risk Factors Associated With Mortality in Consecutive Patients With Bacterial Bloodstream Infection: Impact of MDR and XDR Bacteria. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa461.	0.9	41
95	Inspiratory Effort and Lung Mechanics in Spontaneously Breathing Patients with Acute Respiratory Failure due to COVID-19: A Matched Control Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 725-728.	5.6	41
96	Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 728-734.	2.5	40
97	Mucorales-Specific T Cells in Patients with Hematologic Malignancies. <i>PLoS ONE</i> , 2016, 11, e0149108.	2.5	40
98	Discontinuation of Secondary Prophylaxis for <i>Pneumocystis carinii</i> Pneumonia in Human Immunodeficiency Virus-Infected Patients: A Randomized Trial by the CIOP Study Group. <i>Clinical Infectious Diseases</i> , 2003, 36, 645-651.	5.8	39
99	Discontinuation of Initial Antiretroviral Therapy in Clinical Practice. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 263-271.	2.1	39
100	Tocilizumab for severe COVID-19 pneumonia – Authors' reply. <i>Lancet Rheumatology</i> , The, 2020, 2, e660-e661.	3.9	39
101	Two fatal cases of acute liver failure due to HSV-1 infection in COVID-19 patients following immunomodulatory therapies. <i>Clinical Infectious Diseases</i> , 2021, 73, e252-e255.	5.8	39
102	RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies. <i>Vascular Pharmacology</i> , 2020, 135, 106805.	2.1	39
103	Cytomegalovirus blood reactivation in COVID-19 critically ill patients: risk factors and impact on mortality. <i>Intensive Care Medicine</i> , 2022, 48, 706-713.	8.2	39
104	Monocyte Distribution Width (MDW) as novel inflammatory marker with prognostic significance in COVID-19 patients. <i>Scientific Reports</i> , 2021, 11, 12716.	3.3	38
105	Cervical cancer risk in women living with HIV across four continents: A multicohort study. <i>International Journal of Cancer</i> , 2020, 146, 601-609.	5.1	37
106	Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol. <i>Trials</i> , 2020, 21, 574.	1.6	37
107	Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT). <i>Clinical Microbiology and Infection</i> , 2021, 27, 389-395.	6.0	37
108	Changes in Mitochondrial Rna Production in Cells Treated with Nucleoside Analogues. <i>Antiviral Therapy</i> , 2005, 10, 191-195.	1.0	37

#	ARTICLE	IF	CITATIONS
109	Upregulation of nuclear-encoded mitochondrial LON protease in HAART-treated HIV-positive patients with lipodystrophy: implications for the pathogenesis of the disease. <i>Aids</i> , 2010, 24, 841-850.	2.2	35
110	Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA. <i>Journal of Clinical Virology</i> , 2016, 82, 94-100.	3.1	35
111	Lower Frailty Is Associated with Successful Cognitive Aging Among Older Adults with HIV. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 157-163.	1.1	35
112	Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium. <i>Lancet HIV</i> , 2021, 8, e711-e722.	4.7	35
113	Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. <i>New Microbiologica</i> , 2010, 33, 195-206.	0.1	35
114	Impact of Pre-Therapy Viral Load on Virological Response to Modern First-Line Haart. <i>Antiviral Therapy</i> , 2013, 18, 867-876.	1.0	34
115	Mortality in Patients With Septic Shock by Multidrug Resistant Bacteria. <i>Journal of Intensive Care Medicine</i> , 2019, 34, 48-54.	2.8	34
116	Metabolic reprogramming shapes neutrophil functions in severe COVID-19. <i>European Journal of Immunology</i> , 2022, 52, 484-502.	2.9	34
117	Predictors of transitions in frailty severity and mortality among people aging with HIV. <i>PLoS ONE</i> , 2017, 12, e0185352.	2.5	33
118	Early awake proning in critical and severe COVID-19 patients undergoing noninvasive respiratory support: A retrospective multicenter cohort study. <i>Pulmonology</i> , 2022, 28, 181-192.	2.1	32
119	Late presentation increases risk and costs of non-infectious comorbidities in people with HIV: an Italian cost impact study. <i>AIDS Research and Therapy</i> , 2017, 14, 8.	1.7	31
120	Novel antiretroviral drugs and renal function monitoring of HIV patients. <i>AIDS Reviews</i> , 2014, 16, 144-51.	1.0	31
121	Deregulation of the CD95/CD95L system in lymphocytes from patients with primary acute HIV infection. <i>Aids</i> , 2000, 14, 345-355.	2.2	30
122	Th1 and Th17 proinflammatory profile characterizes invariant natural killer T cells in virologically suppressed HIV+ patients with low CD4+/CD8+ ratio. <i>Aids</i> , 2016, 30, 2599-2610.	2.2	30
123	Human Immunodeficiency Virus (HIV) Care Models During the Coronavirus Disease 2019 (COVID-19) Era. <i>Clinical Infectious Diseases</i> , 2021, 73, e1222-e1227.	5.8	30
124	Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers. <i>PLoS ONE</i> , 2017, 12, e0173893.	2.5	30
125	Mitochondrial DNA Haplogroups and Incidence of Lipodystrophy in HIV-Infected Patients on Long-Term Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, 113-120.	2.1	29
126	Endogenous control of inflammation characterizes pregnant women with asymptomatic or paucisymptomatic SARS-CoV-2 infection. <i>Nature Communications</i> , 2021, 12, 4677.	12.8	29

#	ARTICLE	IF	CITATIONS
127	Impact of Pre-Analytical Time on the Recovery of Pathogens from Blood Cultures: Results from a Large Retrospective Survey. PLoS ONE, 2017, 12, e0169466.	2.5	29
128	Renal complications in HIV disease: between present and future. AIDS Reviews, 2012, 14, 37-53.	1.0	29
129	Clinical Efficacy of Ceftolozane-Tazobactam Versus Other Active Agents for the Treatment of Bacteremia and Nosocomial Pneumonia due to Drug-Resistant Pseudomonas aeruginosa. Clinical Infectious Diseases, 2020, 71, 1799-1801.	5.8	28
130	Herpes Simplex Virus Re-Activation in Patients with SARS-CoV-2 Pneumonia: A Prospective, Observational Study. Microorganisms, 2021, 9, 1896.	3.6	28
131	Gram-Positive Bloodstream Infections in Liver Transplant Recipients: Incidence, Risk Factors, and Impact on Survival. Transplantation Proceedings, 2007, 39, 1947-1949.	0.6	27
132	The cardiovascular risk management for people living with HIV in Europe. Aids, 2016, 30, 2505-2518.	2.2	27
133	Evaluation of serum (1 \rightarrow 3)- β -d-glucan clinical performance: kinetic assessment, comparison with galactomannan and evaluation of confounding factors. Infection, 2016, 44, 223-233.	4.7	27
134	Safety and efficacy of the Russian COVID-19 vaccine: more information needed. Lancet, The, 2020, 396, e53.	13.7	27
135	Considerations for the optimal management of antibiotic therapy in elderly patients. Journal of Global Antimicrobial Resistance, 2020, 22, 325-333.	2.2	27
136	Incidence, risk factors and outcome of acute kidney injury (AKI) in patients with COVID-19. Clinical and Experimental Nephrology, 2021, 25, 1203-1214.	1.6	27
137	Molecular and cellular immune features of aged patients with severe COVID-19 pneumonia. Communications Biology, 2022, 5, .	4.4	27
138	Mitochondrial DNA Haplogroups and Highly Active Antiretroviral Therapy-Related Lipodystrophy. Clinical Infectious Diseases, 2008, 47, 962-968.	5.8	26
139	The natural history of HIV-associated lipodystrophy in the changing scenario of HIV infection. HIV Medicine, 2014, 15, 587-594.	2.2	26
140	Handling and Processing of Blood Specimens from Patients with COVID-19 for Safe Studies on Cell Phenotype and Cytokine Storm. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2020, 97, 668-673.	1.5	26
141	Acid base disorders in patients with COVID-19. International Urology and Nephrology, 2022, 54, 405-410.	1.4	26
142	Highly Active Antiretroviral Therapy Restores CD4+ V β T-Cell Repertoire in Patients With Primary Acute HIV Infection But Not in Treatment-Naive HIV+ Patients With Severe Chronic Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 213-222.	2.1	25
143	Changing Incidence and Risk Factors for Kaposi Sarcoma by Time Since Starting Antiretroviral Therapy: Collaborative Analysis of 21 European Cohort Studies. Clinical Infectious Diseases, 2016, 63, 1373-1379.	5.8	25
144	Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study. BMC Medicine, 2018, 16, 79.	5.5	24

#	ARTICLE	IF	CITATIONS
145	The dynamic association between Frailty, CD4 and CD4/CD8 ratio in people aging with HIV. <i>PLoS ONE</i> , 2019, 14, e0212283.	2.5	24
146	Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 240-250.	2.1	24
147	COVID-19: Importance of the Awareness of the Clinical Syndrome by Urologists. <i>European Urology</i> , 2020, 78, e40-e41.	1.9	24
148	Patient-reported olfactory recovery after SARS-CoV-2 infection: A 6-month follow-up study. <i>International Forum of Allergy and Rhinology</i> , 2021, 11, 1249-1252.	2.8	24
149	CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 x 10 ⁶ cells/l. <i>Aids</i> , 2005, 19, 287-94.	2.2	24
150	Altered Mitochondrial Rna Production in Adipocytes from HIV-Infected Individuals with Lipodystrophy. <i>Antiviral Therapy</i> , 2005, 10, 91-99.	1.0	24
151	The human immunodeficiency virus (HIV) protease inhibitor indinavir directly affects the opportunistic fungal pathogen <i>Cryptococcus neoformans</i> . <i>FEMS Immunology and Medical Microbiology</i> , 2004, 42, 187-195.	2.7	23
152	T Cell Homeostasis in Centenarians: From the Thymus to the Periphery. <i>Current Pharmaceutical Design</i> , 2010, 16, 597-603.	1.9	23
153	Life Expectancy in the Immune Recovery Era. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 175-181.	2.1	23
154	Antimicrobial stewardship in a Gastroenterology Department: Impact on antimicrobial consumption, antimicrobial resistance and clinical outcome. <i>Digestive and Liver Disease</i> , 2016, 48, 1142-1147.	0.9	22
155	Sex Differences in People Aging With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 284-291.	2.1	22
156	Effects of the Change From Stavudine to Tenofovir in Human Immunodeficiency Virus-Infected Children Treated With Highly Active Antiretroviral Therapy. <i>Pediatric Infectious Disease Journal</i> , 2008, 27, 17-21.	2.0	21
157	Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients. <i>Antiviral Therapy</i> , 2010, 15, 51-59.	1.0	21
158	Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved?. <i>Aids</i> , 2015, 29, 2323-2333.	2.2	21
159	Impact of polypharmacy on antiretroviral prescription in people living with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 511-514.	3.0	21
160	Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1363-1367.	3.0	21
161	Long-Term Impact of the COVID-19 Pandemic on In-Hospital Antibiotic Consumption and Antibiotic Resistance: A Time Series Analysis (2015-2021). <i>Antibiotics</i> , 2022, 11, 826.	3.7	21
162	Immunophenotype of HIV+ patients during CD4 cell-monitored treatment interruption: role of the IL-7/IL-7 receptor system. <i>Aids</i> , 2006, 20, 2021-2032.	2.2	20

#	ARTICLE	IF	CITATIONS
163	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. <i>Clinical Infectious Diseases</i> , 2016, 63, ciw519.	5.8	20
164	Prediction of hard cardiovascular events in HIV patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3515-3518.	3.0	20
165	Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1026-1030.	3.0	20
166	The time to offer treatments for COVID-19. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 505-518.	4.1	20
167	Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study. <i>Frontiers in Medicine</i> , 2021, 8, 639970.	2.6	20
168	Changes in Inflammatory and Atherogenesis Biomarkers With the 2-Drug Regimen Dolutegravir Plus Lamivudine in Antiretroviral Therapy-Experienced, Virologically Suppressed People With HIV-1: A Systematic Literature Review. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac068.	0.9	20
169	T Cell Activation but Not Polyfunctionality after Primary HIV Infection Predicts Control of Viral Load and Length of the Time without Therapy. <i>PLoS ONE</i> , 2012, 7, e50728.	2.5	19
170	Mortality in migrants living with HIV in western Europe (1997-2013): a collaborative cohort study. <i>Lancet HIV</i> , 2015, 2, e540-e549.	4.7	19
171	A frailty index predicts post-liver transplant morbidity and mortality in HIV-positive patients. <i>AIDS Research and Therapy</i> , 2017, 14, 37.	1.7	19
172	Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy. <i>BMC Public Health</i> , 2018, 18, 870.	2.9	19
173	Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment. <i>Journal of Clinical Virology</i> , 2018, 104, 61-64.	3.1	19
174	Migration and health: A retrospective study about the prevalence of HBV, HIV, HCV, tuberculosis and syphilis infections amongst newly arrived migrants screened at the Infectious Diseases Unit of Modena, Italy. <i>Journal of Infection and Public Health</i> , 2019, 12, 200-204.	4.1	19
175	COVID-19-associated vasculitis and thrombotic complications: from pathological findings to multidisciplinary discussion. <i>Rheumatology</i> , 2020, 59, e147-e150.	1.9	19
176	Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group. <i>New Microbiologica</i> , 2012, 35, 17-25.	0.1	19
177	Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2016. <i>New Microbiologica</i> , 2017, 40, 86-98.	0.1	19
178	Identification and characterization of an aspartyl protease from <i>Cryptococcus neoformans</i> . <i>FEBS Letters</i> , 2007, 581, 3882-3886.	2.8	18
179	Mitochondrial DNA: a proinflammatory "enemy from within" during HIV infection?. <i>Cell Death and Disease</i> , 2012, 3, e307-e307.	6.3	18
180	Analysis of inflammasomes and antiviral sensing components reveals decreased expression of NLRX1 in HIV-positive patients assuming efficient antiretroviral therapy. <i>Aids</i> , 2015, 29, 1937-1941.	2.2	18

#	ARTICLE	IF	CITATIONS
181	Comparative Evaluation of Subtyping Tools for Surveillance of Newly Emerging HIV-1 Strains. <i>Journal of Clinical Microbiology</i> , 2017, 55, 2827-2837.	3.9	18
182	Characterisation of HIV-1 molecular transmission clusters among newly diagnosed individuals infected with non-B subtypes in Italy. <i>Sexually Transmitted Infections</i> , 2019, 95, 619-625.	1.9	18
183	Plea for multitargeted interventions for severe COVID-19. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1122-1123.	9.1	18
184	Efficacy and durability of twoâ€‹<i>vs</i>. threeâ€‹drug integrase inhibitorâ€‹based regimens in virologically suppressed HIVâ€‹infected patients: Data from realâ€‹life ODOACRE cohort. <i>HIV Medicine</i> , 2021, 22, 843-853.	2.2	18
185	Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive Finding. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, 234-237.	2.1	18
186	Exploring viral reservoir: The combining approach of cell sorting and droplet digital PCR. <i>Methods</i> , 2018, 134-135, 98-105.	3.8	18
187	CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies. <i>Clinical Infectious Diseases</i> , 2021, 73, 50-59.	5.8	18
188	Metabolic-Associated Fatty Liver Disease Is Highly Prevalent in the Postacute COVID Syndrome. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac003.	0.9	18
189	Apoptotic Features of Peripheral Blood Granulocytes and Monocytes during Primary, Acute HIV Infection. <i>Experimental Cell Research</i> , 1999, 247, 304-311.	2.6	17
190	CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2869-2878.	3.0	17
191	The Role of the Renin-Angiotensin System in Severe Acute Respiratory Syndrome-CoV-2 Infection. <i>Blood Purification</i> , 2021, 50, 263-267.	1.8	17
192	Ceftazidime/avibactam and ceftolozane/tazobactam for the treatment of extensively drug-resistant <i>Pseudomonas aeruginosa</i> post-neurosurgical infections: three cases and a review of the literature. <i>Infection</i> , 2021, 49, 549-553.	4.7	17
193	A five-component infection control bundle to permanently eliminate a carbapenem-resistant <i>Acinetobacter baumannii</i> spreading in an intensive care unit. <i>Antimicrobial Resistance and Infection Control</i> , 2021, 10, 123.	4.1	17
194	Kinetics of CD4 cells after discontinuation of antiretroviral therapy in patients with virological failure and a CD4 cell count greater than 500 cells/l ⁴ . <i>Aids</i> , 2002, 16, 1551-1554.	2.2	17
195	Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing <i>Klebsiella pneumoniae</i> : a multicentre study. <i>JAC-Antimicrobial Resistance</i> , 2022, 4, dlac022.	2.1	17
196	Predicting the magnitude of short-term CD4 ^{<sup></sup>} T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy. <i>Antiviral Therapy</i> , 2010, 15, 165-175.	1.0	16
197	Survival Outcomes and Effect of Early vs. Deferred cART Among HIV-Infected Patients Diagnosed at the Time of an AIDS-Defining Event: A Cohort Analysis. <i>PLoS ONE</i> , 2011, 6, e26009.	2.5	16
198	CD4+ T-cell differentiation, regulatory T cells and gag-specific T lymphocytes are unaffected by CD4-guided treatment interruption and therapy resumption. <i>Aids</i> , 2011, 25, 1443-1453.	2.2	16

#	ARTICLE	IF	CITATIONS
199	CD4/CD8 ratio is not predictive of multi-morbidity prevalence in HIV-infected patients but identify patients with higher CVD risk. <i>Journal of the International AIDS Society</i> , 2014, 17, 19709.	3.0	16
200	Clinical outcome of kidney transplantation in HIV-infected recipients: a retrospective study. <i>International Journal of STD and AIDS</i> , 2018, 29, 1305-1315.	1.1	16
201	Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment-Experienced People Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 73, e2323-e2333.	5.8	16
202	Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infection-Results of Italian Network of ACuTe HIV Infection (INACTION) Retrospective Study. <i>Pathogens and Immunity</i> , 2020, 5, 8.	3.1	16
203	OUP accepted manuscript. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 265-268.	2.9	16
204	Different Sensitivity to Apoptosis in Cells of Monocytic or Lymphocytic Origin Chronically Infected with Human Immunodeficiency Virus Type-1. <i>Experimental Biology and Medicine</i> , 2003, 228, 1346-1354.	2.4	15
205	Transmitted HIV Type 1 Drug Resistance and Non-B Subtypes Prevalence among Seroconverters and Newly Diagnosed Patients from 1992 to 2005 in Italy. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 41-49.	1.1	15
206	HIV-1 Infection and the Aging of the Immune System: Facts, Similarities and Perspectives. <i>Journal of Experimental and Clinical Medicine</i> , 2011, 3, 143-150.	0.2	15
207	HIV-DNA content in different CD4 + T-cell subsets correlates with CD4 + cell. <i>Aids</i> , 2017, 31, 1387-1392.	2.2	15
208	Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000-14. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2837-2845.	3.0	15
209	Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icoha cohort. <i>PLoS ONE</i> , 2017, 12, e0177402.	2.5	15
210	Better prognosis in females with severe COVID-19 pneumonia: possible role of inflammation as potential mediator. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1137-1144.	6.0	15
211	Plasma Cytokine Atlas Reveals the Importance of TH2 Polarization and Interferons in Predicting COVID-19 Severity and Survival. <i>Frontiers in Immunology</i> , 2022, 13, 842150.	4.8	15
212	Differential down-regulation of CD95 or CD95L in chronically HIV-infected cells of monocytic or lymphocytic origin: cellular studies and molecular analysis by quantitative competitive RT-PCR. <i>FEBS Letters</i> , 1999, 458, 209-214.	2.8	14
213	Markers of cell death-activation in lymphocytes of vertically HIV-infected children naive to highly active antiretroviral therapy: The role of age. <i>Journal of Allergy and Clinical Immunology</i> , 2001, 108, 439-445.	2.9	14
214	Decline of CD4+ T-cell count before start of therapy and immunological response to treatment in antiretroviral-naive individuals. <i>Aids</i> , 2011, 25, 1041-1049.	2.2	14
215	NK-cell phenotype at interruption underlies widely divergent duration of CD4+-guided antiretroviral treatment interruption. <i>International Immunology</i> , 2011, 23, 109-118.	4.0	14
216	Novel genetic association of TNF- β -238 and PDCD1-7209 polymorphisms with long-term non-progressive HIV-1 infection. <i>International Journal of Infectious Diseases</i> , 2013, 17, e845-e850.	3.3	14

#	ARTICLE	IF	CITATIONS
217	Incidence, Timing, and Determinants of Bacterial Pneumonia Among HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 63, 339-345.	2.1	14
218	Cardiovascular disease in women with HIV-1 infection. <i>International Journal of Cardiology</i> , 2017, 241, 50-56.	1.7	14
219	Acute human herpes virus 7 (HHV-7) encephalitis in an immunocompetent adult patient: a case report and review of literature. <i>Infection</i> , 2017, 45, 385-388.	4.7	14
220	Timing of combined antiretroviral treatment initiation in male and female migrants living with HIV in Western Europe. <i>Aids</i> , 2017, 31, 835-846.	2.2	14
221	The extent of Bâ€cell activation and dysfunction preceding lymphoma development in <scp>HIV</scp>â€positive people. <i>HIV Medicine</i> , 2018, 19, 90-101.	2.2	14
222	Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3295-3304.	3.0	14
223	¹⁸ Fluoride-based molecular imaging of coronary atherosclerosis in HIV infected patients. <i>Atherosclerosis</i> , 2020, 297, 127-135.	0.8	14
224	Twenty-four-hour serum creatinine variation is associated with poor outcome in the novel coronavirus disease 2019 (COVID-19) patients. <i>Kidney Research and Clinical Practice</i> , 2021, 40, 231-240.	2.2	14
225	Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults. <i>Aids</i> , 2015, 29, 193-200.	2.2	13
226	HIV MDR is still a relevant issue despite its dramatic drop over the years. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1301-1310.	3.0	13
227	The Impact of COVID-19 on UNAIDS 90â€“90â€“90 Targets: Calls for New HIV Care Models. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab283.	0.9	13
228	Calendar Time Trends in the Incidence and Prevalence of Triple-Class Virologic Failure in Antiretroviral Drug-Experienced People With HIV in Europe. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 59, 294-299.	2.1	13
229	First and second waves among hospitalised patients with COVID-19 with severe pneumonia: a comparison of 28-day mortality over the 1-year pandemic in a tertiary university hospital in Italy. <i>BMJ Open</i> , 2022, 12, e054069.	1.9	13
230	Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2015. <i>New Microbiologica</i> , 2016, 39, 93-109.	0.1	13
231	Decreased mitochondrial DNA content in subcutaneous fat from HIV-infected women taking antiretroviral therapy as measured at delivery. <i>Antiviral Therapy</i> , 2011, 16, 365-72.	1.0	12
232	The Problem of Renal Function Monitoring in Patients Treated With the Novel Antiretroviral Drugs. <i>HIV Clinical Trials</i> , 2014, 15, 87-91.	2.0	12
233	Cohort profile: The Observational cohort for the study of Dolutegravir in Antiretroviral Combination REGimens (ODOACRE). <i>BMJ Open</i> , 2019, 9, e029960.	1.9	12
234	A Retrospective Whole-Genome Sequencing Analysis of Carbapenem and Colistin-Resistant <i>Klebsiella pneumoniae</i> Nosocomial Strains Isolated during an MDR Surveillance Program. <i>Antibiotics</i> , 2020, 9, 246.	3.7	12

#	ARTICLE	IF	CITATIONS
235	The impact of DAA-mediated HCV eradication on CD4 ⁺ and CD8 ⁺ T lymphocyte trajectories in HIV/HCV coinfecting patients: Data from the ICONA Foundation Cohort. <i>Journal of Viral Hepatitis</i> , 2021, 28, 779-786.	2.0	12
236	Persistent disparities in antiretroviral treatment (ART) coverage and virological suppression across Europe, 2004 to 2015. <i>Eurosurveillance</i> , 2018, 23, .	7.0	12
237	HIV-infected long-term nonprogressors display a unique correlative pattern between the interleukin-7/interleukin-7 receptor circuit and T-cell homeostasis. <i>HIV Medicine</i> , 2009, 10, 422-431.	2.2	11
238	Cytometry, immunology, and HIV infection: Three decades of strong interactions. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2013, 83A, 680-691.	1.5	11
239	Who is more likely to respond to dual treatment with pegylated interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis. <i>Journal of Viral Hepatitis</i> , 2013, 20, 790-800.	2.0	11
240	Gastric Mucormycosis in a Liver and Kidney Transplant Recipient: Case Report and Concise Review of Literature. <i>Transplantation Proceedings</i> , 2018, 50, 905-909.	0.6	11
241	A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4≤ 200 cells/uL (the PRADAR study). <i>PLoS ONE</i> , 2019, 14, e0222650.	2.5	11
242	Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts ≤ 200 cells/mm ³ and HIV-RNA >5 log ₁₀ copies/mL. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2732-2741.	3.0	11
243	Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings. <i>Journal of Clinical Virology</i> , 2020, 130, 104534.	3.1	11
244	Liver steatosis and nonalcoholic fatty liver disease with fibrosis are predictors of frailty in people living with HIV. <i>Aids</i> , 2020, 34, 1915-1921.	2.2	11
245	Risk factors for nosocomial rectal colonization with carbapenem-resistant <i>Acinetobacter baumannii</i> in hospital: a matched case-control study. <i>Antimicrobial Resistance and Infection Control</i> , 2021, 10, 69.	4.1	11
246	Anti-Tat immunity defines CD4+ T-cell dynamics in people living with HIV on long-term cART.. <i>EBioMedicine</i> , 2021, 66, 103306.	6.1	11
247	Breakthrough invasive fungal infection after liver transplantation in patients on targeted antifungal prophylaxis: A prospective multicentre study. <i>Transplant Infectious Disease</i> , 2021, 23, e13608.	1.7	11
248	Evidence-based renewal of the Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. <i>New Microbiologica</i> , 2018, 41, 247-255.	0.1	11
249	Mitochondrial membrane potential and nucleosidic inhibitors of HIV reverse transcriptase: a cytometric approach. <i>Mitochondrion</i> , 2004, 4, 271-278.	3.4	10
250	Congenital Pyelectasis in Children Born from Mothers on Tenofovir Containing Therapy During Pregnancy: Report of Two Cases. <i>Infection</i> , 2007, 35, 474-476.	4.7	10
251	Predictive Value of Intracellular HIV-1 DNA Levels During CD4-Guided Treatment Interruption in HIV ⁺ Patients. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 553-558.	1.1	10
252	Liver Enzyme Elevation During Darunavir-Based Antiretroviral Treatment in HIV-1-Infected Patients With or Without Hepatitis C Coinfection: Data from the ICONA Foundation Cohort. <i>HIV Clinical Trials</i> , 2014, 15, 151-160.	2.0	10

#	ARTICLE	IF	CITATIONS
253	Viro-Immunological Response of Drug-Naive HIV-1-Infected Patients Starting a First-Line Regimen with Viraemia >500,000 Copies/ml in Clinical Practice. <i>Antiviral Therapy</i> , 2018, 23, 249-257.	1.0	10
254	Clinical Utility of Epstein-Barr Virus Viral Load Monitoring and Risk Factors for Posttransplant Lymphoproliferative Disorders After Kidney Transplantation: A Single-Center, 10-Year Observational Cohort Study. <i>Transplantation Direct</i> , 2017, 3, e182.	1.6	10
255	Non-Hodgkin lymphoma risk in adults living with HIV across five continents. <i>Aids</i> , 2018, 32, 2777-2786.	2.2	10
256	Construct validation of a Frailty Index, an HIV Index and a Protective Index from a clinical HIV database. <i>PLoS ONE</i> , 2018, 13, e0201394.	2.5	10
257	Acute Myeloid Leukemia in Patients Living with HIV Infection: Several Questions, Fewer Answers. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1081.	4.1	10
258	Piperacillin-tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen). <i>BMJ Open</i> , 2021, 11, e040210.	1.9	10
259	Prospective Study on Incidence, Risk Factors and Outcome of Recurrent <i>Clostridioides difficile</i> Infections. <i>Journal of Clinical Medicine</i> , 2021, 10, 1127.	2.4	10
260	Changes in central adipose tissue after switching to integrase inhibitors. <i>HIV Research and Clinical Practice</i> , 2020, 21, 168-173.	1.1	10
261	Reliable and Accurate CD4+ T Cell Count and Percent by the Portable Flow Cytometer CyFlow MiniPOC and the CD4 Easy Count Kit-Dry, as Revealed by the Comparison with the Gold Standard Dual Platform Technology. <i>PLoS ONE</i> , 2015, 10, e0116848.	2.5	10
262	Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients. <i>PLoS ONE</i> , 2017, 12, e0171611.	2.5	10
263	Two Different Patterns of Mutations are Involved in the Genotypic Resistance Score for Atazanavir Boosted Versus Unboosted by Ritonavir in Multiple Failing Patients. <i>Infection</i> , 2009, 37, 233-243.	4.7	9
264	Magnitude and Determinants of CD4 Recovery After HAART Resumption After 1 Cycle of Treatment Interruption. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 52, 588-594.	2.1	9
265	Successful Treatment of HIV-1 Infection Increases the Expression of a Novel, Short Transcript for IL-18 Receptor β Chain. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, 254-257.	2.1	9
266	Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens. <i>HIV Medicine</i> , 2017, 18, 21-32.	2.2	9
267	Managing antiretroviral therapy in the elderly HIV patient. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 1171-1181.	3.1	9
268	Establishing a hepatitis C continuum of care among HIV/hepatitis C virus coinfected individuals in EuroSIDA. <i>HIV Medicine</i> , 2019, 20, 264-273.	2.2	9
269	Treating cancer with immunotherapy in HIV-positive patients: A challenging reality. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 145, 102836.	4.4	9
270	A patient-centred approach to deprescribing antiretroviral therapy in people living with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3425-3432.	3.0	9

#	ARTICLE	IF	CITATIONS
271	TOCID-19 - A multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. Study protocol. Contemporary Clinical Trials, 2020, 98, 106165.	1.8	9
272	NLRP3 and IL-1 β Gene Expression Is Elevated in Monocytes From HIV-Treated Patients With Neurocognitive Disorders. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 86, 496-499.	2.1	9
273	Inverse Correlation Between Vascular Calcification and Bone Mineral Density in Human Immunodeficiency Virus-Infected Patients. Calcified Tissue International, 2013, 93, 413-418.	3.1	8
274	European AIDS Clinical Society Standard of Care meeting on HIV and related coinfections: The Rome Statements. HIV Medicine, 2016, 17, 445-452.	2.2	8
275	Evolution of HIV-1 transmitted drug resistance in Italy in the 2007-2014 period: A weighted analysis. Journal of Clinical Virology, 2018, 106, 49-52.	3.1	8
276	Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients. Clinical Microbiology and Infection, 2019, 25, 1443-1446.	6.0	8
277	The Interplay Between Age and Frailty in People Living With HIV: Results From an 11-Year Follow-up Observational Study. Open Forum Infectious Diseases, 2019, 6, ofz199.	0.9	8
278	Altered Expression of PYCARD, Interleukin 1 β , Interleukin 18, and NAIP in Successfully Treated HIV-Positive Patients With a Low Ratio of CD4+ to CD8+ T Cells. Journal of Infectious Diseases, 2019, 219, 1743-1748.	4.0	8
279	Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE. Clinical Infectious Diseases, 2021, 73, 195-202.	5.8	8
280	Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients During Lamivudine Plus Dolutegravir Maintenance Therapy in Clinical Practice. Open Forum Infectious Diseases, 2021, 8, ofab103.	0.9	8
281	No need for secondary <i>Pneumocystis jirovecii</i> pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/ μ L. Journal of the International AIDS Society, 2021, 24, e25726.	3.0	8
282	Endobronchial valve positioning for alveolar-pleural fistula following ICU management complicating COVID-19 pneumonia. BMC Pulmonary Medicine, 2021, 21, 307.	2.0	8
283	Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium. PLoS ONE, 2020, 15, e0243625.	2.5	8
284	What have we learned from the first to the second wave of COVID-19 pandemic? An international survey from the ESCMID Study Group for Infection in the Elderly (ESGIE) group. European Journal of Clinical Microbiology and Infectious Diseases, 2022, 41, 281-288.	2.9	8
285	Italian Consensus Statement on Management of HIV-Infected Individuals with Advanced Disease Naïve to Antiretroviral Therapy. Infection, 2009, 37, 270-82.	4.7	7
286	Drug resistance development differs between HIV-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues. HIV Medicine, 2013, 14, 571-577.	2.2	7
287	Predictors of CD4+ T-Cell Counts of HIV Type 1-Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. Journal of Infectious Diseases, 2013, 207, 759-767.	4.0	7
288	Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group. Infection, 2014, 42, 61-71.	4.7	7

#	ARTICLE	IF	CITATIONS
289	Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus. <i>PLoS ONE</i> , 2015, 10, e0140877.	2.5	7
290	Antiviral activity of sirolimus in an HIV-positive kidney transplant recipient. <i>International Journal of STD and AIDS</i> , 2019, 30, 919-922.	1.1	7
291	Granulicatella adiacens and Abiotrophia defectiva Native Vertebral Osteomyelitis: Three Cases and Literature Review of Clinical Characteristics and Treatment Approach. <i>Case Reports in Infectious Diseases</i> , 2019, 2019, 1-8.	0.5	7
292	AGE OF HIV ACQUISITION AFFECTS THE RISK OF MULTI-MORBIDITY AFTER 25 YEARS OF INFECTION EXPOSURE. <i>Journal of Frailty & Aging,the</i> , 2019, 8, 1-5.	1.3	7
293	Development and validation of a prediction model for tocilizumab failure in hospitalized patients with SARS-CoV-2 infection. <i>PLoS ONE</i> , 2021, 16, e0247275.	2.5	7
294	Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1. <i>HIV Research and Clinical Practice</i> , 2020, 21, 151-167.	1.1	7
295	Has COVID-19 changed the approach to HIV diagnosis?. <i>Medicine (United States)</i> , 2021, 100, e27418.	1.0	7
296	Quantitation of CD95 and CD95L mRNA Expression in Chronic and Acute HIV-1 Infection by Competitive RT-PCR. <i>Annals of the New York Academy of Sciences</i> , 2000, 926, 46-51.	3.8	6
297	Intact parathyroid hormone levels are associated with increased carotid intima media thickness in HIV infected patients. <i>Atherosclerosis</i> , 2014, 237, 618-622.	0.8	6
298	Genotypic Tropism Testing in HIV-1 Proviral DNA Can Provide Useful Information at Low-Level Viremia. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2935-2941.	3.9	6
299	Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study. <i>Drug Design, Development and Therapy</i> , 2016, 10, 1589.	4.3	6
300	Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort. <i>HIV Clinical Trials</i> , 2018, 19, 52-60.	2.0	6
301	Rhodococcus equi Pneumonia in Kidney Transplant Recipient Affected by Acute Intermittent Porphyria: A Case Report. <i>Transplantation Proceedings</i> , 2019, 51, 229-234.	0.6	6
302	Local Epidemics Gone Viral: Evolution and Diffusion of the Italian HIV-1 Recombinant Form CRF60_BC. <i>Frontiers in Microbiology</i> , 2019, 10, 769.	3.5	6
303	Pneumocystosis as a Complication of H1N1 Influenza A Infection in an HIV-Positive Patient on Effective cART. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz105.	0.9	6
304	Epidemiology and Outcomes of Bloodstream Infections in HIV-Patients during a 13-Year Period. <i>Microorganisms</i> , 2020, 8, 1210.	3.6	6
305	Shall We Dance? Extending TANGO™s Results to Clinical Practice. <i>Clinical Infectious Diseases</i> , 2020, 71, e200-e201.	5.8	6
306	Predictors of incomplete viral response and virologic failure in patients with acute and early HIV infection. Results of Italian Network of ACuTe HIV InfectiON (INACTION) cohort. <i>HIV Medicine</i> , 2020, 21, 523-535.	2.2	6

#	ARTICLE	IF	CITATIONS
307	Virological response and resistance profile in highly treatment-experienced HIV-1-infected patients switching to dolutegravir plus boosted darunavir in clinical practice. <i>HIV Medicine</i> , 2021, 22, 519-525.	2.2	6
308	Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV. <i>International Journal of Antimicrobial Agents</i> , 2022, 59, 106492.	2.5	6
309	Resilience and Frailty in People Living With HIV During the COVID Era: Two Complementary Constructs Associated With Health-Related Quality of Life. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 89, S65-S72.	2.1	6
310	Another piece in the COVID-19 treatment puzzle. <i>Lancet, The</i> , 2022, 399, 609-610.	13.7	6
311	The interplay of post-acute COVID-19 syndrome and aging: a biological, clinical and public health approach. <i>Ageing Research Reviews</i> , 2022, 81, 101686.	10.9	6
312	Access to gynecological services and Papanicolaou tests in HIV-infected Italian women: A questionnaire survey. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2006, 18, 376-378.	1.2	5
313	Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI. <i>BMC Infectious Diseases</i> , 2011, 11, 23.	2.9	5
314	Characteristics and outcome predictors of patients involved in an outbreak of <i>Burkholderia cepacia</i> complex. <i>Journal of Hospital Infection</i> , 2013, 85, 73-75.	2.9	5
315	Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort. <i>Journal of the International AIDS Society</i> , 2014, 17, 19825.	3.0	5
316	Epidemiology and clinical outcome of lower respiratory tract infections by respiratory syncytial virus or parainfluenza virus type 3 in adults receiving treatment for either acute leukemia or severe aplastic anemia: a retrospective single center study. <i>Annals of Hematology</i> , 2015, 94, 1931-1934.	1.8	5
317	Immunophenotypic profile and clinical outcome of monoclonal B-cell lymphocytosis in kidney transplantation. <i>Clinical Transplantation</i> , 2018, 32, e13338.	1.6	5
318	Thymus Imaging Detection and Size Is Inversely Associated With Metabolic Syndrome and Frailty in People With HIV. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz435.	0.9	5
319	Compression of frailty in adults living with HIV. <i>BMC Geriatrics</i> , 2019, 19, 229.	2.7	5
320	Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study. <i>HIV Research and Clinical Practice</i> , 2019, 20, 24-33.	1.1	5
321	Acute Myocarditis as the Main Clinical Manifestation of SARS-CoV 2 Infection. <i>Gastroenterology Insights</i> , 2020, 12, 8609.	1.2	5
322	Diagnostic stewardship based on patient profiles: differential approaches in acute versus chronic infectious syndromes. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1373-1383.	4.4	5
323	The role of antimicrobial stewardship in preventing KPC-producing <i>Klebsiella pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, i12-i18.	3.0	5
324	Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort. <i>Viruses</i> , 2022, 14, 163.	3.3	5

#	ARTICLE	IF	CITATIONS
325	Risk Factors for Pulmonary Air Leak and Clinical Prognosis in Patients With COVID-19 Related Acute Respiratory Failure: A Retrospective Matched Control Study. <i>Frontiers in Medicine</i> , 2022, 9, 848639.	2.6	5
326	Increased urinary coproporphyrin excretion observed in patients with differently staged Hodgkin's disease treated with chemotherapy. <i>Pharmacological Research</i> , 2005, 51, 283-288.	7.1	4
327	Absence of liver steatosis in HIV/HCV co-infected patients receiving regimens containing tenofovir or abacavir. <i>Infection</i> , 2013, 41, 425-429.	4.7	4
328	Increased risk of virological failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort. <i>Journal of the International AIDS Society</i> , 2014, 17, 19769.	3.0	4
329	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1352-1360.	3.0	4
330	Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: a Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians. <i>BMC Infectious Diseases</i> , 2017, 17, 734.	2.9	4
331	Bacterial pneumonia in patients with liver cirrhosis, with or without HIV co-infection: a possible definition of antibiotic prophylaxis associated pneumonia (APAP). <i>Infectious Diseases</i> , 2018, 50, 125-132.	2.8	4
332	The degree of HIV-1 amino acid variability is strictly related to different disease progression rates. <i>Virus Genes</i> , 2018, 54, 493-501.	1.6	4
333	Treatment rate for HCV in the direct-acting antivirals era in HIV co-infected patients: data from an Italian cohort. <i>Minerva Medica</i> , 2018, 109, 203-210.	0.9	4
334	Very High Pre-Therapy Viral Load is a Predictor of Virological Rebound in HIV-1-Infected Patients Starting a Modern First-Line Regimen. <i>Antiviral Therapy</i> , 2019, 24, 321-331.	1.0	4
335	Molecular Imaging of Vascular Calcification with 18F-Sodium-Fluoride in Patients Infected with Human Immunodeficiency Virus. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1183.	4.1	4
336	Optimization strategies for HIV, hepatitis and syphilis testing in Infectious Disease Clinic and Dermatology Unit of Modena: 7-year results of collaboration experience. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 959-965.	2.4	4
337	Darunavir/Cobicistat Is Associated with Negative Outcomes in HIV-Negative Patients with Severe COVID-19 Pneumonia. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 283-291.	1.1	4
338	Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy. <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106406.	2.5	4
339	European Society of Cardiology-Proposed Diagnostic Echocardiographic Algorithm in Elective Patients with Clinical Suspicion of Infective Endocarditis: Diagnostic Yield and Prognostic Implications in Clinical Practice. <i>Journal of Cardiovascular Echography</i> , 2018, 28, 26.	0.4	4
340	Combined Resistance to Ceftolozane-Tazobactam and Ceftazidime-Avibactam in Extensively Drug-Resistant (XDR) and Multidrug-Resistant (MDR) <i>Pseudomonas aeruginosa</i> : Resistance Predictors and Impact on Clinical Outcomes Besides Implications for Antimicrobial Stewardship Programs. <i>Antibiotics</i> , 2021, 10, 1224.	3.7	4
341	State of the Art of Dual Therapy in 2015. <i>AIDS Reviews</i> , 2017, 17, .	1.0	4
342	Acid base disorders in patients with COVID-19. <i>International Urology and Nephrology</i> , 2021, , .	1.4	4

#	ARTICLE	IF	CITATIONS
343	Observational Study on HIV-Infected Subjects Failing HAART Receiving Tenofovir Plus Didanosine as NRTI Backbone. <i>Infection</i> , 2007, 35, 451-456.	4.7	3
344	Timing of Antiretroviral Therapy Initiation after a First AIDS-Defining Event: Temporal Changes in Clinical Attitudes in the ICONA Cohort. <i>PLoS ONE</i> , 2014, 9, e89861.	2.5	3
345	Burden of subclinical heart and lung disease detected on thoracic CT scans of HIV patients on HAART. <i>Journal of the International AIDS Society</i> , 2014, 17, 19716.	3.0	3
346	Effect of abacavir on sustained virologic response to HCV treatment in HIV/HCV co-infected patients, Cohere in Eurocoord. <i>BMC Infectious Diseases</i> , 2015, 15, 498.	2.9	3
347	Benefits and medium-term outcome of the Sorin Pericarbon Freedom stentless aortic prosthesis in cases of acute bacterial endocarditis. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2016, 23, 593-598.	1.1	3
348	Incidence of HCV infection amongst HIV positive men who had sex with men and prevalence data from patients followed at the Infectious Diseases Clinic of Modena, Italy. <i>Digestive and Liver Disease</i> , 2018, 50, 1334-1338.	0.9	3
349	Long-term virological suppression on first-line efavirenz+tenofovir+emtricitabine/lamivudine for HIV-1. <i>Aids</i> , 2019, 33, 745-751.	2.2	3
350	Tocilizumab in COVID-19: finding the optimal route and dose – Authors' reply. <i>Lancet Rheumatology</i> , The, 2020, 2, e739-e740.	3.9	3
351	Epidemiology and clinical outcomes of latent tuberculosis infection in adults affected with acute leukemia or aplastic anemia: a retrospective single-center study. <i>Annals of Hematology</i> , 2020, 99, 2201-2203.	1.8	3
352	Short Communication: Circulating Mitochondrial DNA and Lipopolysaccharide-Binding Protein but Not Bacterial DNA Are Increased in Acute Human Immunodeficiency Virus Infection. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 817-820.	1.1	3
353	Effects of cytokine blocking agents on hospital mortality in patients admitted to ICU with acute respiratory distress syndrome by SARS-CoV-2 infection: retrospective cohort study. <i>Multidisciplinary Respiratory Medicine</i> , 2021, 16, 737.	1.5	3
354	Decrease in Incidence Rate of Hospitalizations Due to AIDS-Defining Conditions but Not to Non-AIDS Conditions in PLWHIV on cART in 2008–2018 in Italy. <i>Journal of Clinical Medicine</i> , 2021, 10, 3391.	2.4	3
355	The impact of tocilizumab on respiratory support states transition and clinical outcomes in COVID-19 patients. A Markov model multi-state study. <i>PLoS ONE</i> , 2021, 16, e0251378.	2.5	3
356	Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, , 1.	2.1	3
357	Integrase strand transfer inhibitor use and cancer incidence in a large cohort setting. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac029.	0.9	3
358	Managing the long surviving HIV patient: a proposal for a multidimensional first-level diagnostic assessment. <i>New Microbiologica</i> , 2018, 41, 112-117.	0.1	3
359	Development of post-COVID-19 cardiovascular events: an analysis of clinical features and risk factors from a single hospital retrospective study. <i>Infezioni in Medicina</i> , 2021, 29, 538-549.	1.1	3
360	Mixed connective tissue disease (Sharp syndrome): Description of two cases. <i>Italian Journal of Neurological Sciences</i> , 1983, 4, 203-205.	0.1	2

#	ARTICLE	IF	CITATIONS
361	Effect of amrinone on myocardial mitochondria function. <i>FEBS Letters</i> , 1988, 233, 400-402.	2.8	2
362	An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy. <i>Journal of the International AIDS Society</i> , 2014, 17, 19771.	3.0	2
363	Monitoring renal function during combination therapy with telaprevir in HIV/HCV co-infected patients with advanced/fibrosis cirrhosis. <i>Journal of the International AIDS Society</i> , 2014, 17, 19627.	3.0	2
364	Decrease of renal function in HCV and HIV/HCV-infected patients with telaprevir-based therapy. <i>Aids</i> , 2015, 29, 2061-2062.	2.2	2
365	Brief Report: Drop in CD4+ Counts Below 200 Cells/ μ L After Reaching (or Starting From) Values Higher than 350 Cells/ μ L in HIV-Infected Patients With Virological Suppression. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 76, 417-422.	2.1	2
366	Indications for starting ART. <i>Lancet HIV</i> , 2018, 5, e157-e158.	4.7	2
367	Genetic divergence of HIV-1 B subtype in Italy over the years 2003-2016 and impact on CTL escape prevalence. <i>Scientific Reports</i> , 2018, 8, 15739.	3.3	2
368	Reply to De Greef et al. <i>Clinical Infectious Diseases</i> , 2020, 70, 351-353.	5.8	2
369	Rituximab in people living with HIV affected by immune-mediated renal diseases: a case-series. <i>International Journal of STD and AIDS</i> , 2020, 31, 1426-1431.	1.1	2
370	Successful treatment of BK virus associated-nephropathy in a human immunodeficiency virus-positive kidney transplant recipient. <i>International Journal of STD and AIDS</i> , 2020, 31, 387-391.	1.1	2
371	Comparison of two perioperative antibiotic schedules in patients undergoing surgical reconstruction with dermal matrix after excision of skin cancer. <i>International Wound Journal</i> , 2020, 17, 937-943.	2.9	2
372	Immunomodulation for the management of severe SARS-CoV2 infections. State of the art and review of the literature. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 151-155.	2.1	2
373	Accuracy of the serological detection of IgG and IgM to SARS-Cov-2: a prospective, cross-sectional study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 1891-1898.	2.9	2
374	Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering. <i>Journal of Healthcare Engineering</i> , 2021, 2021, 1-10.	1.9	2
375	Measles-induced immune amnesia likely recorded in the 18th century. <i>Journal of Clinical Virology</i> , 2021, 141, 104899.	3.1	2
376	Prevalence of HIV-associated neurocognitive disorder (HAND) and its subgroups among HIV-positive persons on anti-retroviral therapy in Iran. <i>Psihologija</i> , 2020, 53, 115-127.	0.6	2
377	Differential course of HIV-1 infection and apolipoprotein E polymorphism. <i>Open Medicine (Poland)</i> , 2007, 2, 404-416.	1.3	1
378	Predictors of emphysema progression in HIV-positive patients. <i>Journal of the International AIDS Society</i> , 2014, 17, 19660.	3.0	1

#	ARTICLE	IF	CITATIONS
379	Effectiveness and durability of darunavir/ritonavir (DRV/r) in DRV/r-experienced HIV-1-infected patients in routine clinical practice. <i>Journal of the International AIDS Society</i> , 2014, 17, 19786.	3.0	1
380	Breast tuberculosis: A case report of primary type mammary tuberculosis. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 2346-2348.	0.5	1
381	Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohorts. <i>Digestive and Liver Disease</i> , 2020, 52, 447-451.	0.9	1
382	The Lisbon patient: exceptional longevity with HIV suggests healthy aging as an ultimate goal for HIV care. <i>BMC Infectious Diseases</i> , 2020, 20, 290.	2.9	1
383	Role of Maraviroc in minimizing the risk of graft rejection in HIV-infected kidney transplant recipients. <i>Transplant Infectious Disease</i> , 2020, 22, e13294.	1.7	1
384	Determinants of loss to care and risk of clinical progression in PLWH who are re-engaged in care after a temporary loss. <i>Scientific Reports</i> , 2021, 11, 9632.	3.3	1
385	Signals were broadly positive for months, but never definitive: the tocilizumab story. <i>Clinical Microbiology and Infection</i> , 2021, , .	6.0	1
386	Risk factors for functional decline among survivors of Gram-negative bloodstream infection: A prospective cohort study. <i>PLoS ONE</i> , 2021, 16, e0259707.	2.5	1
387	Non-B subtypes account for a large proportion of clustered primary HIV-1 infections in Italy. <i>Sexually Transmitted Infections</i> , 2022, , sextrans-2021-055289.	1.9	1
388	Increased excretion of urine coproporphyrins during daunorubicin administration in patients affected by acute myelogenous leukemia. <i>Pharmacological Research</i> , 2003, 48, 515-518.	7.1	0
389	Baseline HIV RNA and the when to start question: time to stop asking this question?. <i>Aids</i> , 2006, 20, 1197-1198.	2.2	0
390	Is There Any Potential for First-Line Etravirine Use? Analysis From a Large Data Set of Antiretroviral Therapy-Naive HIV-Infected Patients Undergoing Resistance Test. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 53, 150-151.	2.1	0
391	Patients presenting with AIDS: still a clinical challenge. <i>Future Virology</i> , 2010, 5, 17-19.	1.8	0
392	Aseptic Osteonecrosis. <i>Transplantation</i> , 2012, 94, e20-e21.	1.0	0
393	Re: Lebentrau S, Gilfrich C, Vetterlein MW, Schumacher H, Spachmann PJ, Brookman-May SD, Fritsche HM, Schostak M, Wagenlehner F, Burger M, May M, MR2 study group (2017) Impact of the medical specialty on knowledge regarding multidrug-resistant organisms and strategies toward antimicrobial stewardship. <i>Int Urol Nephrol</i> 49:1311-1318. <i>International Urology and Nephrology</i> , 2018, 50, 873-874.	1.4	0
394	SAT-159-Genetic determinants in critical domains of NS5A are associated with genotype 1b HCV-induced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 70, e699-e700.	3.7	0
395	Impact of genotypic susceptibility score on cART outcomes during primary HIV infection. <i>Journal of Medical Virology</i> , 2019, 91, 1891-1895.	5.0	0
396	Reply to MacFadden and Hanage and to Pallett et al. <i>Clinical Infectious Diseases</i> , 2019, 69, 1263-1264.	5.8	0

#	ARTICLE	IF	CITATIONS
397	Never Give Up: Lesson learned from a severe COVID-19 patient. <i>Pulmonology</i> , 2021, 27, 257-260.	2.1	0
398	Efficient T-Cell Compartment in HIV-Positive Patients Receiving Orthotopic Liver Transplant and Immunosuppressive Therapy. <i>Journal of Infectious Diseases</i> , 2021, 223, 482-493.	4.0	0
399	Adherence to lipid-lowering medication in people living with HIV: An outpatient clinic drug direct distribution experience. <i>Journal of Research in Pharmacy Practice</i> , 2021, 10, 10.	0.7	0
400	Re: "No Significant Changes in Weight and Body Fat Mass in Suppressed HIV Infected Patients Switched to Dual Combination Lamivudine Plus Dolutegravir or Raltegravir" by Calza et al. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 333-334.	1.1	0
401	Re: "Methodological evaluation of bias in observational COVID-19 studies on drug effectiveness" by Wolkewitz et al. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1043-1044.	6.0	0
402	Genotypic HIV-1 tropism determination might help to identify people with exhausted treatment options and advanced disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 3272-3279.	3.0	0
403	Incidence, Temporal Trends, and Predictors of Thrombocytopenia Among HIV-Infected Persons Treated with Combined Antiretroviral Therapy (cART). <i>Blood</i> , 2010, 116, 69-69.	1.4	0
404	In Virologically Suppressed HIV+ Patients, High CD4/CD8 Ratio and Length of Treatment Independently Correlate to the Intracellular Content of Proviral HIV-DNA in Different Types of CD4+ T Cells. <i>Blood</i> , 2016, 128, 3704-3704.	1.4	0
405	Has COVID-19 changed the approach to HIV diagnosis?: A multicentric Italian experience. <i>Medicine (United States)</i> , 2021, 100, e27418.	1.0	0
406	Association between respiratory distress time and invasive mechanical ventilation in COVID-19 patients: a multicentre regional cohort study. <i>Pulmonology</i> , 2022, , .	2.1	0
407	Title is missing!. , 2019, 14, e0222650.		0
408	Title is missing!. , 2019, 14, e0222650.		0
409	Title is missing!. , 2019, 14, e0222650.		0
410	Title is missing!. , 2019, 14, e0222650.		0